HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC

This article was originally published in The Rose Sheet

Executive Summary

Eric Brass, MD/PhD, Harbor-UCLA Medical Center, became acting chair of the FDA advisory committee and heir apparent upon the four- year term expiration of former Chair Ralph D'Agostino, PhD, Boston University. D'Agostino, whose term expired May 31, continues to participate in the committee as a consultant who may vote on issues on a meeting-by-meeting basis, most recently during the discussions on health care antiseptics ("The Rose Sheet" July 27, p. 8). If Brass is to be the successor, his nomination likely will be approved in about two months, along with nominations to replace three other committee vacancies. Three other NDAC members' terms are in May 1999 and three more in May 2000...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel